A total of 89 patients were identified within the study period. However, three patients had incomplete documentation and remained unreachable through the contact details provided in their records. Additionally, five patients opted not to participate in the study. Consequently, the study included 81 participants, out of which 43 (53.1%) were male and 38 (46.9%) were female. The patients' average age was 13.6 ± 4.4 years, while the mean age at the time of diagnosis was 10.3 ± 4.2 years. The mean weight percentile for patients at the time of diagnosis, as per WHO growth curves, was 41.9 ± 26.8. In our study, 2 patients had optic nerve fenestration, and 5 patients underwent shunting. The median lumbar CSF opening pressure in our patient was 39 cmH2O, with an interquartile range of 23.5 - 60 cmH2O, also the lowest and the highest recorded intracranial pressure being 7 and 130 cmH2O, respectively. The duration of patient follow-up was 3.1 ± 1.5 years.
To assess the normality of weight percentiles, the Kolmogorov-Smirnov test was employed, yielding a P-value of < 0.001, indicating non-normal distribution of the data. Despite this, the data exhibited a relatively symmetrical skewness of 0.273. The largest proportion of weight percentile values fell within the < 10% range (20 patients). Also, a significant number of underweight patients were identified in our study (14 patients with weight percentiles < 3). Moreover, 19% of patients met the criteria for being overweight or obese, which is higher than the regional and national averages.
Table 1 provides an overview of the patients' demographic information. Additionally,
Table 1 presents a comprehensive summary of both demographic and clinical particulars of the patients.
| Variables | Values |
|---|
| Age (y) | 13.6 ± 4.4 |
| Weight percentile | 41.9 ± 26.8 |
| Lumbar CSF opening pressure (cmH2O) | 42.9 ± 25.2 |
| Sex | |
| Male | 43 (53.1) |
| Female | 38 (46.9) |
| Clinical signs and symptoms | |
| Headache | 69 (85.2) |
| Nausea/vomiting | 36 (44.4) |
| Strabismus | 23 (28.4) |
| Visual impairment | 38 (46.9) |
| Diplopia | 41 (50.6) |
| Eye pain | 7 (8.6) |
| Photophobia | 8 (9.9) |
| Papilledema | 64 (79.0) |
| Decreased visual acuity | 3 (3.7) |
| Impaired visual field | 2 (2.5) |
| Outcome | |
| Recurrent disease | 13 (16.0) |
| Persistent headache | 13 (16.0) |
| Persistent visual problems | 12 (14.8) |
| Medications | |
| Acetazolamide | 69 (85.2) |
| Topiramate | 9 (11.1) |
| Corticosteroids | 26 (32.1) |
| Antiepileptics | 6 (15.8) |
| Mannitol | 5 (13.2) |
z Abbreviation: CSF; cerebrospinal fluid.
a Values are expressed as No. (%) or mean ± SD.
Out of the total participants, 13 (16.0%) experienced recurrent episodes of IIH, while 68 (84.0%) did not encounter such recurrences. The most prevalent clinical symptom reported by patients was headache (85.2%), followed by diplopia (50.6%), visual impairment (46.9%), nausea and/or vomiting (44.4%), strabismus (28.4%), photophobia (9.9%), and ophthalmodynia (8.6%). Papilledema was the predominant clinical sign observed among patients (79.0%). Furthermore, 2 (2.5%) patients also reported experiencing visual field defects.
In terms of medical history, three (3.7%) patients had a previous diagnosis of attention deficit hyperactivity disorder (ADHD). Among the patient cohort, 71 patients (87.7%) were managed medically, while others required interventional procedures, including ventriculoperitoneal shunt insertion, shunt replacements, therapeutic lumbar punctures, or even optic nerve sheath fenestration. Among the treatments, 70 patients received acetazolamide, with this being the sole medication for 35 (43.2%) patients. In addition to acetazolamide, other medical agents such as topiramate, dexamethasone, methyl prednisolone, and mannitol were employed for treatment in other patients. Patients who received acetazolamide as monotherapy exhibited lower lumbar puncture opening pressure compared to those who needed combination therapy. However, this difference was not statistically significant (34.37 ± 29.10 cmH2O vs. 44.52 ± 26.02 cmH2O, respectively, P = 0.163).
The relationship between sex and various signs, symptoms, and outcomes of the disease was assessed using the chi-square test and Fisher’s exact test. The summarized results of these tests are presented in
Table 2.
| Variables | Male (N = 43) | Female (N = 38) | P-Value |
|---|
| Headache | 38 (88.4) | 31 (81.6) | 0.390 |
| Nausea and/or vomiting | 18 (41.9) | 18 (47.4) | 0.619 |
| Strabismus | 10 (23.3) | 13 (34.2) | 0.275 |
| Visual impairment | 23 (53.5) | 15 (39.5) | 0.207 |
| Diplopia | 21 (48.8) | 20 (52.6) | 0.733 |
| Eye pain | 3 (7.0) | 4 (10.5) | 0.701 |
| Photophobia | 3 (7.0) | 5 (13.2) | 0.464 |
| Papilledema | 35 (81.4) | 29 (76.3) | 0.575 |
| Decreased visual acuity | 1 (2.3) | 2 (5.3) | 0.598 |
| Impaired visual field | 1 (2.3) | 1 (2.6) | > 0.999 |
| Recurrence | 11 (25.6) | 2 (5.3) | 0.013 |
| Persistent headache | 10 (23.3) | 3 (7.9) | 0.060 |
| Persistent visual problems | 6 (14.0) | 6 (15.8) | 0.816 |
a Values are expressed as No. (%).
b A P-value below 0.05 is indicative of statistical significance.
The results showed that recurrence was more frequent in male patients, but the signs and symptoms of the patients did not differ between male and female patients. The outcome of the disease regarding persistent headache and visual problems also did not differ between male and female patients. Chi-square test and Fisher’s exact test were also used to assess the relationship between recurrence and different signs, symptoms, and outcomes of this disease. Most of the patients who experienced recurrent episodes were male, which was significantly different (25.6% of males and 5.3% of females experienced recurrence, P-value = 0.013) (see
Table 2). Patients with and without recurrent episodes differed significantly regarding presentation with strabismus (0% in recurrent disease vs. 33.82% in non-recurrent disease, P-value = 0.013). The results of these comparisons are summarized in
Table 3.
| Variables | Recurrence (N = 13) | No Recurrence (N = 68) | P-Value b |
|---|
| Sex | | | 0.013 |
| Male | 11 (84.6) | 32 (47.1) | |
| Female | 2 (15.4) | 36 (52.9) | |
| Headache | 13 (100) | 56 (82.4) | 0.101 |
| Nausea and/or vomiting | 6 (46.2) | 30 (44.1) | 0.892 |
| Strabismus | 0 (0.0) | 23 (33.8) | 0.013 |
| Visual impairment | 9 (69.2) | 29 (42.6) | 0.078 |
| Diplopia | 4 (30.8) | 37 (54.4) | 0.118 |
| Eye pain | 2 (15.4) | 5 (7.4) | 0.345 |
| Photophobia | 3 (23.1) | 5 (7.4) | 0.082 |
| Papilledema | 11 (84.6) | 53 (77.9) | 0.588 |
| Decreased visual acuity | 0 (0.0) | 3 (4.4) | > 0.999 |
| Impaired visual field | 0 (0.0) | 2 (2.9) | > 0.999 |
| Persistent headache | 4 (30.8) | 9 (13.2) | 0.115 |
| Persistent visual problems | 3 (23.1) | 9 (13.2) | 0.360 |
a Values are expressed as No. (%).
b A P-value below 0.05 is indicative of statistical significance.
The mean weight percentile for patients was found to be 41.6 ± 36.1 for males and 42.4 ±3 8.4 for females, demonstrating no statistically significant difference (P = 0.975). Furthermore, despite the slightly higher mean intracranial pressure among female patients compared to male patients (34.82 ± 22.41 cmH
2O for boys and 44.38 ± 31.14 cmH
2O for girls), this difference was not statistically significant (P = 0.141). To assess the connection between weight percentile and lumbar puncture opening pressure, a Pearson’s correlation test was performed, indicating a non-significant positive correlation (P = 0.094, r = 0.220). Interestingly, patients presenting with visual impairment and impaired visual fields were comparatively older than those without these symptoms (P = 0.005 and P = 0.030, respectively). Conversely, patients experiencing persistent headaches exhibited higher weight percentiles (61.6 ± 3 6.2 vs. 38.3 ± 35.7, P = 0.027).
Table 4 summarizes the comparison of age, weight percentile, and CSF opening pressure based on clinical presentation and outcome of the disease.
| Variables | Age | P-Value | Weight Percentile | P-Value c | CSF Opening Pressure | P-Value d |
|---|
| Sex | | 0.154 | | 0.975 | | 0.141 |
| Male | 9.81 ± 3.65 | | 41.59 ± 36.10 | | 34.82 ± 22.41 | |
| Female | 10.89 ± 4.77 | | 42.41 ± 38.41 | | 44.38 ± 31.14 | |
| Headache | | 0.304 | | 0.665 | | 0.887 |
| No | 8.53 ± 5.88 | | 40.71 ± 42.68 | | 37.75 ± 29.77 | |
| Yes | 10.63 ± 3.83 | | 42.13 ± 36.10 | | 39.38 ± 26.85 | |
| Nausea/vomiting | | | | 0.402 | | 0.903 |
| No | 10.06 ± 4.22 | 0.492 | 38.21 ± 34.96 | | 38.82 ± 23.51 | |
| Yes | 10.64 ± 4.26 | | 50.83 ± 40.38 | | 39.63 ± 30.98 | |
| Strabismus | | 0.071 | | 0.322 | | 0.891 |
| No | 9.87 ± 4.43 | | 38.21 ± 34.96 | | 38.85 ± 24.93 | |
| Yes | 11.46 ± 3.46 | | 50.83 ± 40.38 | | 39.88 ± 31.34 | |
| Visual impairment | | 0.005 | | 0.539 | | 0.614 |
| No | 9.11 ± 3.77 | | 39.82 ± 38.00 | | 40.78 ± 29.98 | |
| Yes | 11.68 ± 4.33 | | 44.75 ± 35.57 | | 37.51 ± 23.72 | |
| Diplopia | | 0.143 | | 0.511 | | 0.119 |
| No | 9.46 ± 4.81 | | 38.66 ± 36.79 | | 33.68 ± 23.26 | |
| Yes | 11.16 ± 3.42 | | 45.00 ± 37.06 | | 43.57 ± 29.15 | |
| Eye pain | | 0.649 | | 0.891 | | 0.091 |
| No | 10.21 ± 4.31 | | 42.27 ± 36.76 | | 36.75 ± 25.29 | |
| Yes | 11.43 ± 3.26 | | 37.54 ± 41.29 | | 65.17 ± 33.15 | |
| Photophobia | | 0.605 | | 0.346 | | 0.390 |
| No | 10.20 ± 3.99 | | 43.13 ± 36.50 | | 38.11 ± 26.90 | |
| Yes | 11.38 ± 6.21 | | 26.73 ± 41.40 | | 47.54 ± 27.86 | |
| Papilledema | | 0.740 | | 0.176 | | 0.461 |
| No | 9.73 ± 4.74 | | 32.42 ± 39.02 | | 44.93 ± 33.24 | |
| Yes | 10.48 ± 4.10 | | 44.85 ± 35.96 | | 37.76 ± 25.33 | |
| Decreased visual acuity | | 0.339 | | > 0.999 | | 0.787 |
| No | 10.23 ± 4.25 | | 42.03 ± 37.06 | | 38.81 ± 26.48 | |
| Yes | 12.67 ± 3.26 | | 34.83 ± N/A | | 52.00 ± 53.74 | |
| Impaired visual field | | 0.030 | | 0.824 | | 0.521 |
| No | 10.18 ± 4.18 | | 42.26 ± 36.97 | | 38.90 ± 27.26 | |
| Yes | 16.00 ± 0.00 | | 19.77 ± N/A | | 49.00 ± 15.56 | |
| Recurrence | | 0.289 | | 0.900 | | 0.286 |
| No | 10.04 ± 4.25 | | 37.29 ± 35.68 | | 37.87 ± 28.05 | |
| Yes | 11.77 ± 3.90 | | 61.55 ± 36.25 | | 45.58 ± 20.81 | |
| Persistent headache | | 0.380 | | 0.027 | | 0.082 |
| No | 10.41 ± 4.53 | | 38.29 ± 35.68 | | 40.90 ± 28.36 | |
| Yes | 9.85 ± 2.09 | | 61.55 ± 36.25 | | 30.00 ± 15.74 | |
| Persistent visual problem | | 0.774 | | 0.106 | | 0.844 |
| No | 10.33 ± 4.25 | | 38.66 ± 36.41 | | 39.48 ± 27.00 | |
| Yes | 10.25 ± 2.96 | | 58.84 ± 35.61 | | 37.64 ± 28.104 | |
a Values are expressed as mean ± SD.
b A P-value below 0.05 is indicative of statistical significance.
c This P-value serves as an indicator of the statistical significance of the observed disparity in weight percentile between two distinct groups for instance differences between genders, presence of headache, or other relevant groupings.
d This P-value serves as an indicator of the statistical significance of the observed disparity in CSF Opening Pressure between two distinct groups for instance differences between genders, presence of headache, or other relevant groupings.
Even after receiving treatment at the hospital, nine patients (11.1%) continued to experience headaches, while another nine patients (11.1%) still faced visual impairments. In an endeavor to appraise the effectiveness of our data-based model in prognosticating the persistence of headache and visual problems, a binary logistic regression test was conducted.
For the model predicting persistent headache, the Omnibus tests of model coefficients yielded a P-value of 0.261. This outcome implies that our model lacked the ability to predict the persistence of headaches accurately. On the contrary, when a binary logistic regression was performed for predicting the persistence of visual problems, the Omnibus tests of model coefficients reported a P-value of 0.007. Notably, the Nagelkerke R
2 value for our model stood at 0.674. The predictive accuracy of our model for future visual problems was 93.8% for patients without persistent visual issues and 54.5% for patients with such problems, resulting in an overall accuracy of 86.4%. A comprehensive outline of the model for predicting future visual problems is presented in
Table 5.
| Variables | B | SE | Wald | df | P-Value | Exp (B) |
|---|
| Age at time of diagnosis | -0.234 | 0.257 | 0.832 | 1 | 0.362 | 0.791 |
| Sex | 1.837 | 1.500 | 1.500 | 1 | 0.221 | 6.278 |
| Weight percentile | 0.040 | 0.020 | 4.022 | 1 | 0.045 | 1.040 |
| Nausea and/or vomiting | 0.613 | 1.261 | 0.236 | 1 | 0.627 | 1.846 |
| Strabismus | 2.256 | 1.923 | 1.376 | 1 | 0.241 | 9.548 |
| Visual impairment | -0.199 | 1.213 | 0.027 | 1 | 0.870 | 0.820 |
| Eye pain | -20.436 | 15303.752 | 0.000 | 1 | 0.999 | 0.000 |
| Photophobia | -18.604 | 16371.180 | 0.000 | 1 | 0.999 | 0.000 |
| Impaired visual field | -12.976 | 40192.970 | 0.000 | 1 | > 0.999 | 0.000 |
| Intracranial pressure | 0.015 | 0.025 | 0.370 | 1 | 0.543 | 1.016 |
| Recurrence | 5.089 | 2.379 | 4.574 | 1 | 0.032 | 162.206 |
| Headache | 20.893 | 13202.473 | 0.000 | 1 | > 0.999 | 1184703310 |
| Diplopia | 2.005 | 1.727 | 1.349 | 1 | 0.245 | 7.429 |
| Papilledema | 20.336 | 8303.748 | 0.000 | 1 | 0.998 | 679230324 |
| Decreased visual acuity | 27.567 | 40192.970 | 0.000 | 1 | > 0.999 | 9.376E + 11 |
aA P-value below 0.05 is indicative of statistical significance.
The results show that only weight percentile and recurrence were significant predictors for future visual problems, with recurrence having stronger predictive power.